- Home
- MTEK vs MYNZ Comparison
MTEK vs MYNZ Comparison
Compare MTEK & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTEK | MYNZ |
|---|---|---|
| Founded | 2008 | 2021 |
| Country | Israel | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 5.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTEK | MYNZ |
|---|---|---|
| Price | $1.78 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 262.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.55 |
| 52 Week High | $4.27 | $5.54 |
Technical Indicators
Market Signals| Indicator | MTEK | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 53.13 | 47.45 |
| Support Level | $1.11 | $0.57 |
| Resistance Level | $1.95 | $1.69 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 22.65 | 68.48 |
Price Performance
Historical ComparisonAbout MTEK Maris-Tech Ltd.
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.